BRIEF-Vivani Medical Announces Rapid Advancement Of NPM-139

Reuters

Aug 05

Aug 5 (Reuters) - Vivani Medical Inc VANI.O:

VIVANI MEDICAL ANNOUNCES RAPID ADVANCEMENT OF NPM-139, A NOVEL SEMAGLUTIDE IMPLANT, FOLLOWING POSITIVE WEIGHT LOSS DATA FROM AN ONGOING PRECLINICAL STUDY OF NPM-139 AND PROMISING RESULTS FROM THE LIBERATE-1 PHASE 1 CLINICAL STUDY OF NPM-115
VIVANI MEDICAL INC - PRIORITIZES ADVANCEMENT OF NPM-139, WITH CLINICAL DEVELOPMENT EXPECTED TO BEGIN IN 2026
VIVANI MEDICAL- NEW NPM-139 PRECLINICAL FEASIBILITY DATA SHOWED ABOUT 20% WEIGHT LOSS MAINTAINED LONGER THAN 6 MONTHS WITH A SINGLE IMPLANT

Source text: ID:nGNX1V4J29

Further company coverage: VANI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557439285"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557439285\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557439285?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557439285","market":"fut","top_or_hot":-1,"title":"BRIEF-Vivani Medical Announces Rapid Advancement Of NPM-139","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vivani Medical Announces Rapid Advancement Of NPM-139</title></head><body><p><span>Aug 5 (Reuters)</span><span> - </span>Vivani Medical Inc <span>VANI.O</span>:</p><ul><li><p>VIVANI MEDICAL ANNOUNCES RAPID ADVANCEMENT OF NPM-139, A NOVEL SEMAGLUTIDE IMPLANT, FOLLOWING POSITIVE WEIGHT LOSS DATA FROM AN ONGOING PRECLINICAL STUDY OF NPM-139 AND PROMISING RESULTS FROM THE LIBERATE-1 PHASE 1 CLINICAL STUDY OF NPM-115</p></li><li><p>VIVANI MEDICAL INC - PRIORITIZES ADVANCEMENT OF NPM-139, WITH CLINICAL DEVELOPMENT EXPECTED TO BEGIN IN 2026</p></li><li><p>VIVANI MEDICAL- NEW NPM-139 PRECLINICAL FEASIBILITY DATA SHOWED ABOUT 20% WEIGHT LOSS MAINTAINED LONGER THAN 6 MONTHS WITH A SINGLE IMPLANT</p></li></ul><p>Source text: <span>ID:nGNX1V4J29</span></p><p>Further company coverage: <span>VANI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vivani Medical Announces Rapid Advancement Of NPM-139</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vivani Medical Announces Rapid Advancement Of NPM-139\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-05 21:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vivani Medical Announces Rapid Advancement Of NPM-139</title></head><body><p><span>Aug 5 (Reuters)</span><span> - </span>Vivani Medical Inc <span>VANI.O</span>:</p><ul><li><p>VIVANI MEDICAL ANNOUNCES RAPID ADVANCEMENT OF NPM-139, A NOVEL SEMAGLUTIDE IMPLANT, FOLLOWING POSITIVE WEIGHT LOSS DATA FROM AN ONGOING PRECLINICAL STUDY OF NPM-139 AND PROMISING RESULTS FROM THE LIBERATE-1 PHASE 1 CLINICAL STUDY OF NPM-115</p></li><li><p>VIVANI MEDICAL INC - PRIORITIZES ADVANCEMENT OF NPM-139, WITH CLINICAL DEVELOPMENT EXPECTED TO BEGIN IN 2026</p></li><li><p>VIVANI MEDICAL- NEW NPM-139 PRECLINICAL FEASIBILITY DATA SHOWED ABOUT 20% WEIGHT LOSS MAINTAINED LONGER THAN 6 MONTHS WITH A SINGLE IMPLANT</p></li></ul><p>Source text: <span>ID:nGNX1V4J29</span></p><p>Further company coverage: <span>VANI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VANI","symbol_name":"Vivani Medical, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nFWN3TX1BI:1","article_id":"2557439285","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557439285","pubTimestamp":1754400336,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Vivani Medical Announces Rapid Advancement Of NPM-139Aug 5 (Reuters) - Vivani Medical Inc VANI.O:VIVANI MEDICAL ANNOUNCES RAPID ADVANCEMENT OF NPM-139, A NOVEL SEMAGLUTIDE IMPLANT, FOLLOWING POS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VANI":"Vivani Medical, Inc.","BK4082":"医疗保健设备"},"translate_title":"简报-Vivani Medical宣布快速推进NPM-139","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VANI":0.9},"content_text":"BRIEF-Vivani Medical Announces Rapid Advancement Of NPM-139Aug 5 (Reuters) - Vivani Medical Inc VANI.O:VIVANI MEDICAL ANNOUNCES RAPID ADVANCEMENT OF NPM-139, A NOVEL SEMAGLUTIDE IMPLANT, FOLLOWING POSITIVE WEIGHT LOSS DATA FROM AN ONGOING PRECLINICAL STUDY OF NPM-139 AND PROMISING RESULTS FROM THE LIBERATE-1 PHASE 1 CLINICAL STUDY OF NPM-115VIVANI MEDICAL INC - PRIORITIZES ADVANCEMENT OF NPM-139, WITH CLINICAL DEVELOPMENT EXPECTED TO BEGIN IN 2026VIVANI MEDICAL- NEW NPM-139 PRECLINICAL FEASIBILITY DATA SHOWED ABOUT 20% WEIGHT LOSS MAINTAINED LONGER THAN 6 MONTHS WITH A SINGLE IMPLANTSource text: ID:nGNX1V4J29Further company coverage: VANI.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}